Rangering i aksjer
#39521
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Aksjekurs
$0.056
Sist synkronisert: 2023-08-21
Handel Novan, Inc. (NOVN)
Pris NOVN pris med markedsverdi på B
Markedsverdi av Novan, Inc.(NOVN)
Markedsverdi: $451.38K
Per August 2026 har Novan, Inc. en markedsverdi på $451.38K. Dette gjør Novan, Inc. til det 39521st mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Novan, Inc. fra 2016 til 2026
NOVN sammenlignet med topp 5 mest populære stocks
| Pris på NOVN |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.470T
|
+1,211,742,781.38%
|
|
|
|
|
$4.467T
|
+989,652,399.15%
|
|
|
|
|
$4.174T
|
+924,809,850.85%
|
|
|
|
|
$3.700T
|
+819,729,559.49%
|
|
|
|
|
$2.854T
|
+632,362,192.30%
|
